Trial Profile

Platform Adaptive trial of Novel antivirals for early treatment of COVID-19 in the community

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 21 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Molnupiravir (Primary)
Indications COVID 2019 infections
Focus Therapeutic Use
Acronyms PANORAMIC
Sponsors Merck & Co

Most Recent Events

01 Jan 2025 Results (n=25783, data cut-off: 27 Apr 2022) assessing health outcomes from the longer term follow-up after 3 months and 6 months, presented in The Lancet Infectious Diseases
09 Apr 2024 Planned End Date changed from 30 Sep 2024 to 31 Mar 2025.
08 Mar 2024 Planned End Date changed from 31 Mar 2024 to 30 Sep 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com